Form 4: Versant Reports Large LENZ (LENZ) Stock Sales at ~$41.59–$43.00
Rhea-AI Filing Summary
Versant entities reported multiple sales of LENZ Therapeutics common stock on 09/18/2025. The Form 4 shows a series of dispositions at weighted-average prices of $41.5908 (sales between $41.25 and $42.24) and $43.0038 (sales between $42.25 and $43.24), plus small sales at $43.30.
Reported transactions include direct and indirect sales: for example, 49,479 and 40,907 shares sold directly and 24,370 and 20,148 shares sold indirectly across the two weighted-average-price groups. The filings list 1,224,718; 1,183,811; and related post-transaction beneficial ownership totals for the reporting entities, and note 842,162 shares held indirectly by Versant Vantage II, L.P.
Positive
- Full, timely disclosure of multiple related-party transactions under Section 16
- Clear footnotes explaining ownership chains and who may share voting and dispositive power
- Signer identification and manual signatures provided for the reporting entities
Negative
- Substantial sales by affiliated Versant entities on 09/18/2025 that reduce reported beneficial ownership
- Multiple related entities sold shares, which could be interpreted as a coordinated reduction in holdings
Insights
TL;DR: Large, disclosed insider sales by multiple Versant entities on the same date; transparency is clear but sales reduce reported holdings.
The Form 4 details coordinated dispositions by related Versant entities on 09/18/2025 at weighted-average prices in two price bands ($41.5908 and $43.0038) and small additional sales at $43.30. The filing clearly distinguishes direct and indirect holdings and provides post-transaction ownership counts (e.g., 1,224,718 and 1,183,811 shares reported following certain sales). Footnotes explain ownership chains among Versant funds and general partners, which is important for understanding voting and dispositive power. The disclosure is complete per Section 16 requirements and offers the issuer or SEC staff the ability to request granular per-transaction pricing from the reporting person.
TL;DR: Form 4 shows compliant, multi-entity reporting of sales with clear attribution and standard ownership disclaimers.
The submission includes signatures from the relevant Versant GP entities and identifies Max Eisenberg as Chief Operating Officer signing on behalf of multiple general partner entities. Footnotes (2–5) explain the indirect ownership relationships and disclaimers of beneficial ownership except for pecuniary interests, which is typical in fund GP structures. The filing does not include any amendments or plans (e.g., 10b5-1) checked, and the transactions are reported as sales on a single execution date. From a governance perspective, the filing meets disclosure norms for insider transactions but documents a material reduction in economic exposure across several affiliated funds.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 49,479 | $41.5908 | $2.06M |
| Sale | Common Stock | 24,370 | $41.5908 | $1.01M |
| Sale | Common Stock | 40,907 | $43.0038 | $1.76M |
| Sale | Common Stock | 20,148 | $43.0038 | $866K |
| Sale | Common Stock | 268 | $43.30 | $12K |
| Sale | Common Stock | 132 | $43.30 | $6K |
| holding | Common Stock | -- | -- | -- |
Footnotes (5)
- F1. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $41.25 to $42.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- F2. These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
- F3. These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
- F4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $42.25 to $43.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
- F5. These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Each of VV II GP-GP and VV II GP may be deemed to share voting, investment and dispositive power over the shares held by VV II and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
AI-generated analysis. How Rhea-AI works. Not financial advice.
